Recombinant BCGs for tuberculosis and bladder cancer
Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination program...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Singh, Alok K. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement - Li, Yaoyao ELSEVIER, 2022, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:39 ; year:2021 ; number:50 ; day:8 ; month:12 ; pages:7321-7331 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.vaccine.2021.09.040 |
|---|
| Katalog-ID: |
ELV056109016 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056109016 | ||
| 003 | DE-627 | ||
| 005 | 20230626042731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2021.09.040 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica |
| 035 | |a (DE-627)ELV056109016 | ||
| 035 | |a (ELSEVIER)S0264-410X(21)01231-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 630 |a 640 |q VZ |
| 084 | |a 48.00 |2 bkl | ||
| 100 | 1 | |a Singh, Alok K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recombinant BCGs for tuberculosis and bladder cancer |
| 264 | 1 | |c 2021transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. | ||
| 520 | |a Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. | ||
| 650 | 7 | |a Tuberculosis |2 Elsevier | |
| 650 | 7 | |a Immunotherapy |2 Elsevier | |
| 650 | 7 | |a BCG |2 Elsevier | |
| 650 | 7 | |a Vaccine |2 Elsevier | |
| 650 | 7 | |a Trained immunity |2 Elsevier | |
| 650 | 7 | |a Bladder cancer |2 Elsevier | |
| 700 | 1 | |a Srikrishna, Geetha |4 oth | |
| 700 | 1 | |a Bivalacqua, Trinity J. |4 oth | |
| 700 | 1 | |a Bishai, William R. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Li, Yaoyao ELSEVIER |t Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |d 2022 |g Amsterdam |w (DE-627)ELV007884451 |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:50 |g day:8 |g month:12 |g pages:7321-7331 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.vaccine.2021.09.040 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-FOR | ||
| 936 | b | k | |a 48.00 |j Land- und Forstwirtschaft: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 50 |b 8 |c 1208 |h 7321-7331 |g 11 | ||
| author_variant |
a k s ak aks |
|---|---|
| matchkey_str |
singhalokksrikrishnageethabivalacquatrin:2021----:eobnnbgfrueclssn |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
48.00 |
| publishDate |
2021 |
| allfields |
10.1016/j.vaccine.2021.09.040 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica (DE-627)ELV056109016 (ELSEVIER)S0264-410X(21)01231-7 DE-627 ger DE-627 rakwb eng 630 640 VZ 48.00 bkl Singh, Alok K. verfasserin aut Recombinant BCGs for tuberculosis and bladder cancer 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer Elsevier Srikrishna, Geetha oth Bivalacqua, Trinity J. oth Bishai, William R. oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:39 year:2021 number:50 day:8 month:12 pages:7321-7331 extent:11 https://doi.org/10.1016/j.vaccine.2021.09.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 39 2021 50 8 1208 7321-7331 11 |
| spelling |
10.1016/j.vaccine.2021.09.040 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica (DE-627)ELV056109016 (ELSEVIER)S0264-410X(21)01231-7 DE-627 ger DE-627 rakwb eng 630 640 VZ 48.00 bkl Singh, Alok K. verfasserin aut Recombinant BCGs for tuberculosis and bladder cancer 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer Elsevier Srikrishna, Geetha oth Bivalacqua, Trinity J. oth Bishai, William R. oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:39 year:2021 number:50 day:8 month:12 pages:7321-7331 extent:11 https://doi.org/10.1016/j.vaccine.2021.09.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 39 2021 50 8 1208 7321-7331 11 |
| allfields_unstemmed |
10.1016/j.vaccine.2021.09.040 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica (DE-627)ELV056109016 (ELSEVIER)S0264-410X(21)01231-7 DE-627 ger DE-627 rakwb eng 630 640 VZ 48.00 bkl Singh, Alok K. verfasserin aut Recombinant BCGs for tuberculosis and bladder cancer 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer Elsevier Srikrishna, Geetha oth Bivalacqua, Trinity J. oth Bishai, William R. oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:39 year:2021 number:50 day:8 month:12 pages:7321-7331 extent:11 https://doi.org/10.1016/j.vaccine.2021.09.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 39 2021 50 8 1208 7321-7331 11 |
| allfieldsGer |
10.1016/j.vaccine.2021.09.040 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica (DE-627)ELV056109016 (ELSEVIER)S0264-410X(21)01231-7 DE-627 ger DE-627 rakwb eng 630 640 VZ 48.00 bkl Singh, Alok K. verfasserin aut Recombinant BCGs for tuberculosis and bladder cancer 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer Elsevier Srikrishna, Geetha oth Bivalacqua, Trinity J. oth Bishai, William R. oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:39 year:2021 number:50 day:8 month:12 pages:7321-7331 extent:11 https://doi.org/10.1016/j.vaccine.2021.09.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 39 2021 50 8 1208 7321-7331 11 |
| allfieldsSound |
10.1016/j.vaccine.2021.09.040 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica (DE-627)ELV056109016 (ELSEVIER)S0264-410X(21)01231-7 DE-627 ger DE-627 rakwb eng 630 640 VZ 48.00 bkl Singh, Alok K. verfasserin aut Recombinant BCGs for tuberculosis and bladder cancer 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer Elsevier Srikrishna, Geetha oth Bivalacqua, Trinity J. oth Bishai, William R. oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:39 year:2021 number:50 day:8 month:12 pages:7321-7331 extent:11 https://doi.org/10.1016/j.vaccine.2021.09.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 39 2021 50 8 1208 7321-7331 11 |
| language |
English |
| source |
Enthalten in Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement Amsterdam volume:39 year:2021 number:50 day:8 month:12 pages:7321-7331 extent:11 |
| sourceStr |
Enthalten in Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement Amsterdam volume:39 year:2021 number:50 day:8 month:12 pages:7321-7331 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Land- und Forstwirtschaft: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Tuberculosis Immunotherapy BCG Vaccine Trained immunity Bladder cancer |
| dewey-raw |
630 |
| isfreeaccess_bool |
false |
| container_title |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
| authorswithroles_txt_mv |
Singh, Alok K. @@aut@@ Srikrishna, Geetha @@oth@@ Bivalacqua, Trinity J. @@oth@@ Bishai, William R. @@oth@@ |
| publishDateDaySort_date |
2021-01-08T00:00:00Z |
| hierarchy_top_id |
ELV007884451 |
| dewey-sort |
3630 |
| id |
ELV056109016 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056109016</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626042731.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.vaccine.2021.09.040</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056109016</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0264-410X(21)01231-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">48.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Singh, Alok K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recombinant BCGs for tuberculosis and bladder cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tuberculosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BCG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trained immunity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bladder cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Srikrishna, Geetha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bivalacqua, Trinity J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bishai, William R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Li, Yaoyao ELSEVIER</subfield><subfield code="t">Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV007884451</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:39</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:50</subfield><subfield code="g">day:8</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:7321-7331</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.vaccine.2021.09.040</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">48.00</subfield><subfield code="j">Land- und Forstwirtschaft: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">39</subfield><subfield code="j">2021</subfield><subfield code="e">50</subfield><subfield code="b">8</subfield><subfield code="c">1208</subfield><subfield code="h">7321-7331</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| author |
Singh, Alok K. |
| spellingShingle |
Singh, Alok K. ddc 630 bkl 48.00 Elsevier Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer Recombinant BCGs for tuberculosis and bladder cancer |
| authorStr |
Singh, Alok K. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007884451 |
| format |
electronic Article |
| dewey-ones |
630 - Agriculture & related technologies 640 - Home & family management |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
630 640 VZ 48.00 bkl Recombinant BCGs for tuberculosis and bladder cancer Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer Elsevier |
| topic |
ddc 630 bkl 48.00 Elsevier Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer |
| topic_unstemmed |
ddc 630 bkl 48.00 Elsevier Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer |
| topic_browse |
ddc 630 bkl 48.00 Elsevier Tuberculosis Elsevier Immunotherapy Elsevier BCG Elsevier Vaccine Elsevier Trained immunity Elsevier Bladder cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
g s gs t j b tj tjb w r b wr wrb |
| hierarchy_parent_title |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
| hierarchy_parent_id |
ELV007884451 |
| dewey-tens |
630 - Agriculture 640 - Home & family management |
| hierarchy_top_title |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007884451 |
| title |
Recombinant BCGs for tuberculosis and bladder cancer |
| ctrlnum |
(DE-627)ELV056109016 (ELSEVIER)S0264-410X(21)01231-7 |
| title_full |
Recombinant BCGs for tuberculosis and bladder cancer |
| author_sort |
Singh, Alok K. |
| journal |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
| journalStr |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
7321 |
| author_browse |
Singh, Alok K. |
| container_volume |
39 |
| physical |
11 |
| class |
630 640 VZ 48.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Singh, Alok K. |
| doi_str_mv |
10.1016/j.vaccine.2021.09.040 |
| dewey-full |
630 640 |
| title_sort |
recombinant bcgs for tuberculosis and bladder cancer |
| title_auth |
Recombinant BCGs for tuberculosis and bladder cancer |
| abstract |
Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. |
| abstractGer |
Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. |
| abstract_unstemmed |
Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR |
| container_issue |
50 |
| title_short |
Recombinant BCGs for tuberculosis and bladder cancer |
| url |
https://doi.org/10.1016/j.vaccine.2021.09.040 |
| remote_bool |
true |
| author2 |
Srikrishna, Geetha Bivalacqua, Trinity J. Bishai, William R. |
| author2Str |
Srikrishna, Geetha Bivalacqua, Trinity J. Bishai, William R. |
| ppnlink |
ELV007884451 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.vaccine.2021.09.040 |
| up_date |
2024-07-06T19:27:23.667Z |
| _version_ |
1803859047133216768 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056109016</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626042731.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.vaccine.2021.09.040</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001602.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056109016</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0264-410X(21)01231-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">48.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Singh, Alok K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recombinant BCGs for tuberculosis and bladder cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacillus Calmette–Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tuberculosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BCG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trained immunity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bladder cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Srikrishna, Geetha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bivalacqua, Trinity J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bishai, William R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Li, Yaoyao ELSEVIER</subfield><subfield code="t">Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV007884451</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:39</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:50</subfield><subfield code="g">day:8</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:7321-7331</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.vaccine.2021.09.040</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">48.00</subfield><subfield code="j">Land- und Forstwirtschaft: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">39</subfield><subfield code="j">2021</subfield><subfield code="e">50</subfield><subfield code="b">8</subfield><subfield code="c">1208</subfield><subfield code="h">7321-7331</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| score |
7.401575 |